Observational studyJournal of infection and public health2021

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.

Rahmet Guner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.